BB710 Metabolite 2

**BB710 Metabolite 2** is a BalinBac Therapeutics investigational COVID-19 program within the BB-700 series. It is described as a combination of repurposed generic drugs intended for oral and inhalation delivery, with proposed multi-mechanistic antiviral activity against SARS-CoV-2 involving viral entry or attachment, spike or protease processes, RNA-dependent RNA polymerase activity, and host metabolic-response pathways. The precise active-ingredient composition and the specific molecular targets of this individual BB710 metabolite program have not been publicly disclosed. BalinBac describes the broader BB-700 series as combinations of two or more generic drugs for COVID-19. ([balinbac.com](https://www.balinbac.com/pipeline))